{"paper_id":"3bbab77b-26c8-44e9-bfac-009c92e70d9b","body_text":"The International Glossary on Infertility and Fertility Care defines infertility as the inability to conceive after 1 or more years of regular, unprotected sexual intercourse, or impairment in one’s ability to reproduce as an individual or with a partner. Although the benchmark of duration is 1 year, infertility evaluation and treatment may be initiated earlier in certain populations, including patients older than 35 years of age and those with conditions known to impair fertility, such as the newly redesignated polyendocrine metabolic ovarian syndrome (PMOS), formerly polycystic ovary syndrome.\nPrimary infertility refers to infertility in a woman with no prior clinical pregnancy, whereas secondary infertility refers to infertility in a woman who has previously achieved a clinical pregnancy. Between 2015 and 2019, 8.5% of married women aged 15 to 49 years in the United States experienced infertility. Among married women experiencing infertility, the prevalence of infertility was higher among women with no prior births (19.4%) than among those with one or more prior births (6.0%). During this same time period, 12.2% of all US women aged 15 to 49 received infertility services ranging from education and counseling to assisted reproductive technology (ART).\nThis article focuses on common gynecologic causes of female infertility and provides an overview of available infertility treatment options. It also describes post-treatment complications of ART, with guidance on identifying and addressing these concerns.\nCOMMON CAUSES\nCervical\nCervical scarring and/or stenosis after surgical procedures in which the cervix has been dilated or manipulated may result in decreased cervical mucus production. These changes may impair sperm progression into the uterus.\nUterine\nUterine leiomyomas occur in up to 70% of women. Submucosal fibroids, which distort the uterine cavity by growing under the uterine surface lining, are associated with impaired embryo implantation. Other uterine factors that hinder embryo implantation include Müllerian anomalies (such as a septate uterus), endometrial polyps, and intrauterine scarring or adhesions.\nTubal\nTubal scarring, obstruction, or impaired tubal motility may result from previous sexually transmitted infections or pelvic inflammatory disease.Chlamydia trachomatis has been identified as the most common infectious cause of infertility. Endometriosis and pelvic or abdominal adhesions resulting from previous surgeries can also cause tubal infertility through obstruction or scarring of the fallopian tubes.\nOvulatory dysfunction\nOvulatory dysfunction refers to abnormalities in ovulation that result in menstrual disturbances, including amenorrhea, infrequent or irregular menstrual bleeding, and unpredictable variations in menstrual frequency, timing, or flow volume. Ovulatory dysfunction can be classified into three broad categories: hypothalamic-pituitary dysfunction, normogonadotropic ovulatory dysfunction, and primary ovarian insufficiency (POI). Hypothalamic-pituitary dysfunction occurs when signaling from the hypothalamus or pituitary gland is disrupted, such as with functional hypothalamic amenorrhea or hyperprolactinemia. Normogonadotropic ovulatory dysfunction constitutes the predominant category of ovulatory disorders and is frequently associated with PMOS. POI involves impaired ovarian function and depletion of ovarian follicles. Ovulatory dysfunction exists on a spectrum and may range from irregular ovulation to complete anovulation.\nPMOS, reported in 5% to 10% of women globally, affects 70% of women experiencing anovulation. In addition to impaired ovulation, patients with PMOS have impaired embryo implantation. PMOS features include signs of hyperandrogenism, amenorrhea or irregular and unpredictable variations in menstrual frequency, and evidence of polycystic ovaries on ultrasound. Beyond PMOS, causes of anovulation include obesity and conditions associated with the thyroid, pituitary, and adrenal glands.\nDiminished ovarian reserve\nDiminished ovarian reserve (DOR) is defined as a reduction in the quantity of ovarian follicles relative to the number expected for an individual’s chronological age. Ovarian reserve declines naturally over time due to ovulation and follicular atresia. Oocyte quality also diminishes with age. Although the true cause of DOR remains unknown, several gynecologic factors are associated with the condition, including history of ovarian surgery, ovarian exposure to radiation, and a family history of premature menopause.\nEndometriosis\nEndometriosis refers to the implantation of endometrial tissue outside the uterine cavity. Endometriosis implants can obstruct the fallopian tubes or impair tubal patency, whereas endometriomas (ovarian implants) may adversely affect oocyte quality. Endometriosis can also result in adhesions and fibrosis that anatomically distort reproductive organs and hinder embryo implantation. Risk factors for endometriosis include early menarche, nulliparity, short menstrual cycles, heavy menstruation, and a family history of endometriosis.\nTREATMENT MODALITIES\nTreatment options for female infertility are generally classified as low- and high-tech interventions. Treatment is informed by the underlying cause of infertility. In addition, individual preferences and patient-centered socioeconomic factors, including the high cost of treatment, limited insurance coverage, transportation difficulties, inability to take time away from work, and cultural stigma, should be considered.\nLow-tech treatment: Stimulated cycles and intrauterine insemination\nThe two modalities of stimulated menstrual cycles commonly used to achieve successful ovulation are ovulation induction (OI) and controlled ovarian stimulation (COS). In OI, medications are given to stimulate the ovaries to produce one or two eggs at a time. This is frequently recommended for patients with irregular cycles, such as those associated with PMOS. COS differs from OI in that the goal is to produce more than one or two eggs. This method is frequently recommended for couples experiencing infertility due to mild male-factor infertility, typically characterized by slightly reduced sperm count, motility, or morphology, as well as in patients with one blocked fallopian tube, endometriosis, or unexplained infertility. The final treatment decision, however, should be individualized and may be influenced by factors such as prior treatment history, treatment costs, and patient preferences. Both OI and COS can be combined with timed intercourse or intrauterine insemination (IUI).\nIUI is a procedure in which sperm is deposited directly into the uterus. It is less invasive than in vitro fertilization (IVF) and can be performed during a stimulated cycle or a natural menstrual cycle; however, natural-cycle IUI does not require the frequent monitoring that stimulated-cycle IUI requires because ovulation occurs without pharmacologic ovarian stimulation and can be timed by detecting the endogenous luteinizing hormone (LH) surge. IUI is often indicated for women with cervical mucus abnormalities, couples affected by low sperm count, or same-sex female couples using donor sperm. In IUI, the sperm sample is washed and centrifuged in an andrology laboratory. A pellet collected from the bottom of the tube is placed in a culture medium and is then introduced into the uterus via a catheter. Although the pregnancy rate per individual IUI cycle is relatively low (11%), repeated treatment cycles result in an overall cumulative success rate of approximately 19%.\nSeveral medications are frequently used for stimulated-cycle protocols. Clomiphene citrate is a selective estrogen receptor modulator that competes with estrogen at the hypothalamic estrogen receptor level and signals the hypothalamus to release more gonadotropin-releasing hormone (GnRH). After several days of therapy, ovulation is monitored using home ovulation testing or serial blood draws to monitor levels of follicle-stimulating hormone (FSH) and LH. Patients also undergo transvaginal ultrasonography to monitor follicular growth and assess uterine lining thickness. Based on the results, timed intercourse may be recommended or IUI performed.\nOther stimulated-cycle protocols include administration of FSH alone or combined FSH and LH therapy. These medications are started early in the menstrual cycle and continued until the follicles are fully developed. Alternatively, a combined clomiphene citrate and FSH protocol can be considered, in which the patient takes the combination of medications early in the menstrual cycle, followed by FSH injections, until follicular maturation. Medication protocols continue to evolve as advancements in this field emerge.\nFollicular growth is generally observed at a rate of 1 to 2 mm per day on transvaginal ultrasound. On average, about 14 days of stimulation are required for follicles to measure between 18 and 24 mm, although stimulation may require as few as 7 days or more than 20, depending on the patient. Estrogen, progesterone, and LH levels are also frequently measured during this monitoring period and correlated with ultrasound findings to facilitate real-time medication dose adjustments when clinically indicated. When follicular maturation has been achieved, based on factors such as follicular size, the number of developing follicles, hormone levels, and the relative risk of spontaneous ovulation, the patient receives a trigger shot, which induces final oocyte maturation and prepares the follicles for ovulation or egg retrieval. The trigger shot typically consists of a human chorionic gonadotropin (hCG) injection or a GnRH agonist injection such as leuprolide. hCG mimics a naturally occurring LH surge, whereas GnRH induces an endogenous LH surge. Ovulation triggering is timed with either intercourse or IUI.\nHigh-tech treatment: IVF\nIVF is a sophisticated ART that facilitates fertilization by combining oocytes and sperm outside the body. This process involves culturing embryos, which are then transferred to the uterine cavity. IVF is often utilized in the treatment of female infertility resulting from tubal dysfunction, unexplained infertility, and age-related subfertility. It is also recommended for patients in need of fertility preservation due to medical disorders, social factors, or inherited genetic disorders.\nIVF success rates vary considerably based on factors such as maternal age, embryo quality, infertility diagnosis, use of donor oocytes, and preimplantation genetic testing. In the United States, live birth rates per IVF cycle are highest in patients younger than 35 years (approximately 40% to 50%) and progressively decline with advancing age, falling to less than 5% to 10% in patients older than 42 years.\nIVF IN FOCUS\nIVF consists of a series of coordinated steps designed to maximize the likelihood of fertilization, embryo development, and successful implantation. Although specific protocols vary among patients, most IVF cycles follow the same general sequence, summarized below and illustrated in Figure 1.\nStep-by-step\nSteps include COS, oocyte retrieval, fertilization, and embryo culture and transfer.\nCOS: COS involves three phases: suppression, stimulation, and trigger. Suppression is typically achieved with oral contraceptives, GnRH agonists such as leuprolide, and GnRH antagonists such as cetrorelix acetate or ganirelix acetate. Oral contraceptives suppress endogenous hormone production or are used to schedule a cycle. GnRH antagonists prevent premature ovulation. GnRH agonists initially stimulate the pituitary gland but after several days cause suppressive effects. As a result, they prevent premature ovulation and the development of a single dominant follicle.\nIn the stimulation phase, multiple follicles are produced. The ideal number of follicles varies by patient and clinical circumstances but generally ranges from 8 to 20. This is accomplished through FSH injections, along with ongoing monitoring through blood tests and transvaginal ultrasonography. Once the follicles reach maturity, a trigger injection is administered. Egg retrieval is usually scheduled approximately 36 hours after the injection.\nEgg retrieval: Egg retrieval may be performed using a variety of anesthesia and analgesia approaches, including moderate sedation (conscious sedation), monitored anesthesia care, regional anesthesia, or, less commonly, general anesthesia, to minimize patient discomfort. During retrieval, healthy, mature eggs are collected from ovarian follicles by inserting an ultrasound-guided needle through the vaginal wall into the ovary and follicles. The aspirated fluid is immediately examined by an embryologist for the presence of oocytes. Intramuscular or vaginal progesterone is typically initiated on the day of or shortly after egg retrieval to support the endometrium. Progesterone supplementation must then be continued after egg retrieval to maintain the uterine lining.\nFertilization: Fertilization is achieved by introducing prepared sperm into a sample containing a mature oocyte or by injecting a single sperm directly into the cytoplasm of an oocyte via intracytoplasmic sperm injection (ICSI). ICSI is primarily indicated in cases of severe male-factor infertility, including low sperm count, poor motility, or abnormal morphology. It may also be considered in cases of prior failed fertilization with conventional IVF.\nEmbryo development and transfer: The fertilized egg progresses through several developmental stages, becoming a 4-cell embryo, then an 8-cell embryo, then a morula, and finally a blastocyst. Embryo transfer is typically performed at the blastocyst stage, approximately 3 to 5 days after oocyte retrieval. There is a significant attrition throughout the processes of egg retrieval, fertilization, and transfer. For example, if eight oocytes are retrieved, only five may fertilize; of those, only three might reach the cleavage stage, with two potentially developing into blastocysts, and ultimately one being selected for transfer. Common criteria used to assess embryo quality for selection include morphology, rate of development, degree of blastocyst expansion, and quality of the inner cell mass and trophectoderm. The embryo deemed to have the highest implantation potential is selected for transfer. Transfer is typically performed without anesthesia using a speculum and a fitted catheter that places the embryo into the uterine cavity. Progesterone supplementation is continued to support the uterine lining and, if pregnancy occurs, generally throughout the first trimester.\nAdditional considerations\nPreimplantation genetic testing of the embryo\nIn selected cases, specifically couples at risk, embryos may undergo genetic testing before transfer to evaluate for inherited genetic disorders or chromosomal abnormalities. Preimplantation genetic testing (PGT) involves biopsy of one or more cells from an embryo, most commonly at the blastocyst stage, for genetic analysis. Contemporary techniques typically sample trophectoderm cells while avoiding biopsy of the inner cell mass that later develops into the fetus.\nPGT can identify abnormalities such as aneuploidy (PGT-A), single-gene disorders (PGT-M), and structural chromosomal rearrangements (PGT-SR). PGT-A is commonly considered in cases of advanced maternal age, recurrent pregnancy loss, recurrent IVF failure, and male-factor infertility associated with chromosomal abnormalities. PGT-M is recommended when one or both genetic parents are carriers of or affected by a specific inherited disorder, such as cystic fibrosis or sickle cell disease. PGT-SR is performed when a parent carries a balanced chromosomal rearrangement, such as a translocation or inversion, associated with increased risk of miscarriage or chromosomally unbalanced offspring.\nBecause false-positive and false-negative PGT results remain possible, confirmatory prenatal diagnostic testing is recommended following pregnancy achieved after transfer of a PGT-tested embryo.\nSurrogacy and gestational carriers\nSurrogacy and gestational carrier arrangements offer reproductive options for individuals or couples who are unable to or choose not to carry a pregnancy themselves. In traditional surrogacy, the surrogate provides the egg and carries the pregnancy, whereas in gestational surrogacy, which is more commonly practiced, an embryo created via IVF is transferred to a carrier who has no genetic connection to the fetus.\nEffective surrogacy arrangements require thorough medical, psychological, and legal evaluations to protect the interests of all parties involved. Surrogacy and gestational carrier arrangements are regulated at the state level; therefore, laws surrounding surrogacy may vary significantly across the United States. Although some states have well-established legal protections and guidance for gestational carrier agreements, others have limited or unclear laws, making legal counseling an important part of the process.\nPOST-TREATMENT COMPLICATIONS IN ACUTE CARE\nAs with any medical intervention, infertility treatments and procedures are associated with risks and complications that vary by modality (Table 1). These factors should be considered during shared decision-making when discussing infertility treatment options with patients.\nTABLE 1.\nInfertility treatments and associated potential complications\n| Treatment type | Selected potential complications |\n|---|---|\n| Ovulation induction with oral agents | Multiple gestation, ovarian cyst formation, hot flashes, mood changes |\n| Ovulation induction with timed intercourse | Multiple gestation, EP, ovarian cysts |\n| Ovulation induction with IUI | Multiple gestation, EP, infection, ovarian cysts |\n| IVF | OHSS, hemoperitoneum, EP and HP, emotional and financial stress |\n| Oocyte retrieval | Hemoperitoneum, infection, injury to pelvic structures, anesthesia-related complications |\n| Embryo transfer | Uterine cramping, spotting, EP |\n| PGT | Embryo loss from biopsy, false-positive or false-negative results, ethical concerns |\n| Gestational carrier | Medical risks to the carrier (pregnancy-related complications), psychological stress, legal disputes |\nOvarian hyperstimulation syndrome\nOvarian hyperstimulation syndrome (OHSS) is a potentially serious complication of IVF. A severe form of OHSS occurs in approximately 3% to 8% of IVF cycles and is associated with COS using gonadotropins. Most affected patients are White (55.7%), privately insured (87.7%), between the ages of 25 and 39 years (84.6%), and hospitalized in urban settings (95%). These demographic characteristics likely reflect the population most commonly undergoing this procedure and should not be interpreted as independent risk factors for this complication. OHSS most often develops following administration of an ovulation trigger shot, especially hCG, which increases production of vascular endothelial growth factor, leading to increased vascular permeability. Early OHSS typically develops within 3 to 7 days of hCG administration, whereas late OHSS typically develops 10 to 14 days after hCG administration.\nPatients with OHSS can present with abdominal distension, pelvic pain, nausea, vomiting, and rapid weight gain, reflective of ovarian enlargement and third-spacing of fluid into the peritoneal cavity. Patients may also develop ascites, pleural effusions, dyspnea, oliguria, and peripheral edema resulting from intravascular volume depletion and capillary leak. Other symptoms may include chest pain, neurologic symptoms, or syncope, all of which warrant a workup for thromboembolic complications such as pulmonary embolism, stroke, or renal infarct.\nEvaluation of a patient with suspected OHSS starts with assessment of hemodynamic stability, volume status, respiratory function, and urine output. Physical examination should be guided by the patient’s symptoms but should include assessment of abdominal distension, tenderness, respiratory effort, and signs of dehydration. Laboratory testing may show hemoconcentration, electrolyte abnormalities such as hyponatremia, and impaired renal function. Pelvic ultrasound is typically positive for bilaterally enlarged ovaries with multiple follicles and varying degrees of ascites. Pleural effusion may also be noted on point-of-care ultrasound or other forms of imaging.\nOHSS is commonly stratified as mild, moderate, severe, or critical, with management guided by severity. Mild cases benefit from supportive therapy such as oral hydration and outpatient clinical follow-up, whereas moderate cases typically require hospital admission, inpatient monitoring, and supportive care. Careful IV fluid resuscitation, correction of electrolyte abnormalities, serial monitoring of hematocrit and renal function, and close tracking of urine output are principles of management for moderate to severe OHSS management. Critical OHSS necessitates emergency care and multidisciplinary care in an intensive care unit (ICU) to address life-threatening organ failures, including acute kidney injury, thromboembolism, or acute respiratory distress syndrome. Because OHSS is associated with markedly increased risk of thrombosis, thromboprophylaxis should be considered in patients with severe disease or prolonged immobility.\nOvarian torsion\nCompared with the general population, ovarian torsion occurs more frequently in patients undergoing ART because COS promotes the development of multiple follicles, resulting in ovarian enlargement and an increased risk of torsion. In this population, ovarian torsion most commonly occurs during or shortly after ovarian stimulation, after oocyte retrieval, or in early pregnancy when ovaries remain enlarged. Patients with OHSS are also at high risk of ovarian torsion due to increased ovarian size and weight, which predispose the ovary to rotation.\nPatients with ovarian torsion present with sudden-onset, severe, unilateral lower abdominal pain, often with nausea and vomiting. Pain may be intermittent if torsion is partial or transient, which can delay diagnosis. In patients undergoing ART, symptoms may be mistakenly attributed to postprocedural discomfort or ovarian enlargement, further contributing to diagnostic delays. Physical examination may reveal localized adnexal tenderness. Transvaginal ultrasonography with Doppler is the primary imaging modality and may demonstrate reduced or absent ovarian blood flow; however, normal Doppler findings do not exclude ovarian torsion.\nOvarian torsion is a surgical emergency and is typically managed laparoscopically to detorse the affected ovary and restore perfusion. A delay in diagnosis may result in ovarian infarction, loss of ovarian function, hemoperitoneum, infection, or peritonitis, potentially resulting in infertility.\nEctopic and heterotopic pregnancy\nHeterotopic pregnancy (HP) is a rare and frequently missed complication in which an intrauterine pregnancy and an ectopic pregnancy (EP) occur simultaneously. ART increases the risk of EP and is therefore associated with a higher incidence of HP, with reported rates of HP as high as 1 in 100 pregnancies. EP and HP may develop in patients undergoing ART due to ovulation induction, embryo stage at transfer, and transfer of multiple embryos. Common indications for IVF, including tubal abnormalities and endometriosis, further increase the risk of EP and HP after treatment. Early diagnosis and intervention are crucial, but clinical symptoms are often nonspecific. Patients with EP may be asymptomatic or present with vaginal bleeding and unilateral, localized lower abdominal or pelvic pain that can progress to generalized pain following tubal rupture. Patients with HP present similarly but carry a higher risk of hypovolemic shock due to delayed recognition.\nTransvaginal ultrasound is the first-line imaging modality for diagnosing EP and HP and may detect an adnexal gestational sac and significant intraperitoneal bleeding if rupture has occurred. Color Doppler use increases diagnostic specificity and sensitivity. Early HP diagnosis is particularly challenging because the presence of an intrauterine pregnancy may reduce suspicion for a concurrent EP. Diagnostic laparoscopy or laparotomy is indicated in hemodynamically unstable patients with nondefinitive clinical presentation or sonography.\nSome hemodynamically stable EPs can be managed conservatively with the administration of methotrexate. Surgical management via laparoscopic salpingostomy or salpingectomy is indicated in patients with hemodynamic instability, hemoperitoneum, fetal cardiac activity outside of the uterus, or high initial β-hCG levels. The management goal of HP is to terminate the EP while minimizing risk to the patient and the intrauterine pregnancy, which is commonly achieved through laparoscopy. Methotrexate is contraindicated in HP due to toxicity to the viable intrauterine fetus. Expectant management of EP can be considered in asymptomatic patients with declining β-hCG levels because the risk of tubal rupture is low but is generally avoided in HP because of the higher maternal risk.\nHemoperitoneum\nAlthough rare, IVF carries a risk for development of hemoperitoneum, commonly from ruptured EP, bleeding after transvaginal oocyte retrieval, or complications of ovarian hyperstimulation. The incidence of hemoperitoneum resulting solely from instrumentation during oocyte retrieval is approximately 0.05%. Ovarian stimulation enlarges and hypervascularizes the ovaries, and the increased incidence of EP among patients undergoing IVF further contributes to the risk of intraperitoneal hemorrhage.\nPatient assessment begins with an evaluation of hemodynamic stability and a focused review of systems. Shoulder-tip pain, abdominal tenderness, hypotension, tachycardia, and dyspnea without significant external blood loss are common manifestations. Peritoneal signs and evidence of shock may also be seen on examination. Focused assessment with sonography for trauma and transvaginal ultrasound may reveal intraperitoneal free fluid in the pouch of Douglas; in more severe cases, fluid may spread to the uterovesical fold and Morrison pouch.\nMild hemoperitoneum in hemodynamically stable patients can be managed conservatively with rest, hemostatic agents, close monitoring of hemoglobin and hematocrit levels, and serial ultrasound. Moderate to severe cases require prompt treatment with IV fluid resuscitation, blood product administration, surgical laparoscopy, and targeted hemostasis via electrocoagulation. Laparotomy is reserved for cases in which hemostasis is not achieved.\nCONCLUSION\nFemale infertility is a complex medical condition, with approximately 12% of reproductive-age women in the US utilizing infertility services each year. With advances in medicine, especially in the field of ART, the options for individuals and couples seeking infertility services have expanded. PAs across disciplines should be knowledgeable in common infertility causes, along with ART procedures and their potential complications, in order to educate individuals and couples effectively, participate in shared decision-making, and treat and manage patients receiving infertility services appropriately.\nREFERENCES\n1\nZegers-Hochschild F, Adamson GD, Dyer S, et alThe International Glossary on Infertility and Fertility Care, 2017†‡§. Hum Reprod. 2017;32(9):1786–1801. doi:10.1093/humrep/dex234.2\nTeede HJ, Khomami MB, Morman R, et alPolyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329–2339. doi:10.1016/S0140-6736(26)00717-8.3\nFastStats. March 17, 2025. Accessed December 23, 2025. https://www.cdc.gov/nchs/fastats/infertility.htm.4\nNSFG - Listing I - Key Statistics from the National Survey of Family Growth. December 16, 2022. Accessed December 23, 2025. https://www.cdc.gov/nchs/nsfg/key_statistics/i-keystat.htm.5\nPhillips K, Olanrewaju RA, Omole F. Infertility: evaluation and management. Am Fam Physician. 2023;107(6):623–630.6\nVitale SG, De Angelis MC, Della Corte L, et alUterine cervical stenosis: from classification to advances in management. Overcoming the obstacles to access the uterine cavity. Arch Gynecol Obstet. 2024;309(3):755–764. doi:10.1007/s00404-023-07126-1.7\nCarson SA, Kallen AN. Diagnosis and management of infertility: a review. JAMA. 2021;326(1):65–76. doi:10.1001/jama.2021.4788.8\nVander Borght M, Wyns C. Fertility and infertility: definition and epidemiology. Clin Biochem. 2018;62:2–10. doi:10.1016/j.clinbiochem.2018.03.012.9\nMunro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408. doi:10.1002/ijgo.12666.10\nMunro MG, Balen AH, Cho S, et alThe FIGO ovulatory disorders classification system. Int J Gynecol Obstet. 2022;159(1):1–20. doi:10.1002/ijgo.14331.11\nDieke AC, Zhang Y, Kissin DM, Barfield WD, Boulet SL. Disparities in assisted reproductive technology utilization by race and ethnicity, United States, 2014: a commentary. J Womens Health. 2017;26(6):605–608. doi:10.1089/jwh.2017.6467.12\nJain M, Singh M. Assisted Reproductive Technology (ART) Techniques. In: StatPearls. StatPearls Publishing; 2025. Accessed September 7, 2025. http://www.ncbi.nlm.nih.gov/books/NBK576409/.13\nZippl AL, Wachter A, Rockenschaub P, Toth B, Seeber B. Predicting success of intrauterine insemination using a clinically based scoring system. Arch Gynecol Obstet. 2022;306(5):1777–1786. doi:10.1007/s00404-022-06758-z.14\nKamel RM. Assisted reproductive technology after the birth of Louise Brown. J Reprod Infertil. 2013;14(3):96–109.15\nUse of exogenous gonadotropins for ovulation induction in anovulatory women: a committee opinion (2020). Accessed December 23, 2025. https://www.asrm.org/practice-guidance/practice-committee-documents/use-of-exogenous-gonadotropins-for-ovulation-induction-in-anovulatory-women-a-committee-opinion-2020/.16\nHilbert SM, Gunderson S. Complications of assisted reproductive technology. Emerg Med Clin North Am. 2019;37(2):239–249. doi:10.1016/j.emc.2019.01.005.17\nLevi-Setti PE, Segni ND, Gargasole C, Ronchetti C, Cirillo F. Ovarian hyperstimulation: diagnosis, prevention, and management. Semin Reprod Med. 2021;39:170–179. doi:10.1055/s-0041-1736492.18\nTimmons D, Montrief T, Koyfman A, Long B. Ovarian hyperstimulation syndrome: a review for emergency clinicians. Am J Emerg Med. 2019;37(8):1577–1584. doi:10.1016/j.ajem.2019.05.018.19\nNational Summary Report. Accessed May 14, 2026. https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?reportingYear=2022.20\nLiu XM, Zhang F, Lu XS, Xi HT, Zhao JZ. Effects and safety of propofol intravenous anesthesia in transvaginal oocyte retrieval on outcomes of in vitro fertilization and embryo transplantation. Front Endocrinol. 2024;15: doi:10.3389/fendo.2024.1497948.21\nGardner DK, Schoolcraft WB. Culture and transfer of human blastocysts. Curr Opin Obstet Gynecol. 1999;11(3):307–311. doi:10.1097/00001703-199906000-00013.22\nGrading Scales. Accessed May 14, 2026. https://www.asrm.org/asrm-academy/asrm-academy-on-the-go/embryo-data-grading--evaluation/grading-scales/.23\nPreimplantation Genetic Testing. Accessed May 14, 2026. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/03/preimplantation-genetic-testing.24\nESHRE PGT Consortium Steering Committee, Carvalho F, Coonen E, et alESHRE PGT Consortium good practice recommendations for the organisation of PGT†. Hum Reprod Open. 2020;2020(3):hoaa021. doi:10.1093/hropen/hoaa021.25\nFranasiak JM, Forman EJ, Hong KH, et alThe nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril. 2014;101(3):656–663.e1. doi:10.1016/j.fertnstert.2013.11.004.26\nConsideration of the gestational carrier: an Ethics Committee opinion (2023). Accessed December 23, 2025. https://www.asrm.org/practice-guidance/ethics-opinions/consideration-of-the-gestational-carrier-an-ethics-committee-opinion-2023/.27\nRichards EG, Farrell RM, Ricci S, et alUterus transplantation: state of the art in 2021. J Assist Reprod Genet. 2021;38(9):2251–2259. doi:10.1007/s10815-021-02245-7.28\nGestational Carrier Policy in the United States. Accessed May 14, 2026. https://www.asrm.org/advocacy-and-policy/fact-sheets-and-one-pagers/gestational-carrier-policy-in-the-united-states/.29\nLeathersich S, Roche C, Hart R. Minimising OHSS in women with PCOS. Front Endocrinol. 2025;16: doi:10.3389/fendo.2025.1507857.30\nSelter J, Wen T, Palmerola KL, Friedman AM, Williams Z, Forman EJ. Life-threatening complications among women with severe ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 2019;220(6):575.e1–575.e11. doi:10.1016/j.ajog.2019.02.009.31\nOlchowy A, Olchowy C, Łasecki M, et alOvarian hyperstimulation syndrome as a growing diagnostic problem in emergency department settings: a case report. J Emerg Med. 2019;56(2):217–221. doi:10.1016/j.jemermed.2018.11.004.32\nAdams A, Adams C. Ovarian hyperstimulation syndrome: a case report. J Emerg Nurs. 2023;49(1):8–11. doi:10.1016/j.jen.2022.09.006.33\nHsu JC, Huang KL, Tsai NC. Bilateral massive bloody pleural effusions as a rare presentation of ovarian hyperstimulation syndrome: a case report and literature review. Taiwan J Obstet Gynecol. 2025;64(2):348–352. doi:10.1016/j.tjog.2024.03.030.34\nKoh H, Kim SD, Yang H. Ischemic stroke associated with ovarian hyperstimulation syndrome. J Emerg Med. 2021;61(3):320–324. doi:10.1016/j.jemermed.2021.05.001.35\nGrandone E, Bitsadze V, Khizroeva J, et alRisk of thrombosis in women undergoing in vitro fertilization: a narrative review. J Clin Med. 2025;14(4):1053. doi:10.3390/jcm14041053.36\nElmahal M, Lohana P, Anvekar P, Menda MK, Arti. Hyponatremia: an untimely finding in ovarian hyper-stimulation syndrome. Cureus. 2021;13(7):e16556. doi:10.7759/cureus.16556.37\nKhalil MAM, Ghazni MS, Tan J, Naseer N, Khalil MAU. Spontaneous bacterial peritonitis and anasarca in a female patient with ovarian hyperstimulation syndrome complicated by respiratory and kidney failure. Case Rep Gastroenterol. 2016;10(2):423–430. doi:10.1159/000446766.38\nMisiriyyah N, Qurban K, Beevi A, Paulose L, Margossian H. Adnexal torsion associated with recurrent ovarian hyperstimulation syndrome: a case report. Cureus. 2023;15(3):e36344doi:10.7759/cureus.36344.39\nPhillips CH, Wortman JR, Ginsburg ES, Sodickson AD, Doubilet PM, Khurana B. First-trimester emergencies: a radiologist’s perspective. Emerg Radiol. 2018;25(1):61–72. doi:10.1007/s10140-017-1556-9.40\nMaleki A, Khalid N, Patel CR, El-Mahdi E. The rising incidence of heterotopic pregnancy: Current perspectives and associations with in-vitro fertilization. Eur J Obstet Gynecol Reprod Biol. 2021;266:138–144. doi:10.1016/j.ejogrb.2021.09.031.41\nTrindade VD, Hentschke MR, Dornelles VC, et alTubal factor, cleavage stage and more than one embryo transferred were risk factors associated with ectopic pregnancy after assisted reproductive treatment. JBRA Assist Reprod. 2022;26(2):321–328. doi:10.5935/1518-0557.20210074.42\nZhu S, Fan Y, Lan L, Deng T, Zhang Q. Heterotopic pregnancy secondary to in vitro fertilization-embryo transfer: risk factors and pregnancy outcomes. Front Med. 2022;9:864560. doi:10.3389/fmed.2022.864560.43\nFarren J, Al Wattar BH, Jurkovic D. The diagnosis and management of extrauterine and uterine ectopic pregnancy. Hum Reprod Update. 2026;32(1):2–32. doi:10.1093/humupd/dmaf024.44\nHarzif AK, Hyaswicaksono P, Kurniawan RH, Wiweko B. Heterotopic pregnancy: diagnosis and pitfall in ultrasonography. Gynecol Minim Invasive Ther. 2021;10(1):53–56. doi:10.4103/GMIT.GMIT_92_19.45\nMullany K, Minneci M, Monjazeb R, Coiado CO. Overview of ectopic pregnancy diagnosis, management, and innovation. Womens Health. 2023;19:17455057231160349. doi:10.1177/17455057231160349.46\nChen L, Zhang H, Xu Y, Wang Z. Intra-abdominal hemorrhage following ultrasound-guided transvaginal oocyte retrieval: retrospective analysis of 25 cases. AJOG Glob Rep. 2025;5(3):100508. doi:10.1016/j.xagr.2025.100508.47\nStojnic J, Bila J, Tulic L, et alSevere hemoperitoneum due to ovarian bleeding after transvaginal oocyte retrieval with surgical management: a retrospective analysis and comprehensive review of the literature. Medicina (Mex). 2023;59(2):307. doi:10.3390/medicina59020307.48\nGhasemian Dizaj Mehr S, Bahadori R. Successful conservative management of massive hemoperitoneum in patients on anticoagulation with ruptured hemorrhagic ovarian cyst: a report of two cases and review of literature. J Obstet Gynecol Cancer Res. 2024;9(2):231–234. doi:10.30699/jogcr.9.2.231.","source_license":"public-domain-us","license_restricted":false}